Multicenter phase II study of MK-2206 in previously treated patients with recurrent and metastatic nasopharyngeal carcinoma
A Phase I Trial of 5Azacitidine and Suberoylanilide hydroxamic acid in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T cell Lymphoma (NCI study).
Phase II study of Cetuximab with Carboplatin in patients with metastatic NPC.
Phase II study of Ifosphamide and Doxorubicin in Patients with Refractory Nasopharyngeal Carcinoma.
NeoPHOEBE: “Pi3k inhibition in Her2 OverExpressing Breast cancEr: A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab + BKM120 in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer”
A Phase I/II study of weekly Paclitaxel and ORZEL (UFT + Leucovorin) in patients with metastatic breast cancer.
Non Small Cell Lung Cancer
Phase II study of Taxotere & Carboplatin combination in resectable metastatic and locally advanced NSCLC.
Phase I study of Gemcitabine in conjunction with Vinorelbine and Radiotherapy in the Management of Stage IIIB or medically non-resectable non-small cell lung cancer (NSCLC).
Phase I/II trial of infusional Gemcitabine in combination with Carboplatin in chemo-naive advanced NSCLC.
A Phase II study of Triapine And Gemcitabine as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Patients Who Had Prior Gemcitabine with Evaluation of the Effect of Triapine on Gemcitabine Pharmacokinetics and Cellular Uptake in Peripheral Mononuclear Cells (NCI study).
Phase II trial of pre-operative Docetaxel, Cisplatin and continuous infusion 5FU in patients with locally advanced gastric adenocarcinoma.
Phase II clinical trial of a novel tubulin-interacting macrolide in advanced local or metastatic gastric cancer (collaboration with a multi-national pharmaceutical company).
A Phase II study of Irofulven as first line therapy in recurrent or metastatic gastric cancer (NCI study).
Survey of angiogenic factors in HCC
A Phase II trial of Thalidomide in unresectable HCC.
Phase II trial of PS-341 in patients with hepatocellular carcinoma (NCI study in collaboration with Mayo Phase II Consortium).
Hepatoma — Validation of CUPI.
Phase II study of biweekly Irinotecan (CPT-11), 5-Fluorouracil (5FU) and Folinic Acid (FA) in unresectable liver metastases from colorectal cancer.
Phase II study of 5-Fluorouracil, Folinic Acid, Gemcitabine and Cisplatin as the second line treatment in patients with metastatic or recurrent colorectal carcinoma.
A Phase II study of Fenretinide in Patients with Hormone Refractory Prostate Cancer (NCI study).
A Phase II Trial of Bevacizumab and Erlotinib in Patients with Advanced Biliary Tumors (NCI study in collaboration with Mayo Phase II Consortium).
Study of genetic predisposition to chemotherapy-related toxicity.
A Phase II Trial of GW786034 in Advanced Thyroid Cancer (NCI study in collaboration with Mayo Phase II Consortium).
MC1282-(NCI 9271) – Phase 2 Trial of Single-agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
Phase I/II trial of Cediranib alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
A Randomized Placebo-Controlled Phase II trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD1775 (MK1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
- A Phase I Trial of 5Azacitidine and Suberoylanilide hydroxamic acid in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T cell Lymphoma (NCI study).
- A Phase II Trial of VELCADE in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma.
- The effect of pharmacogenetics on treatment toxicities and outcomes in East Asian and Caucasian patients undergoing docetaxel or gemcitabine-based chemotherapy.
- A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma (NCI study).
- A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer (NCI study in collaboration with Mayo Phase II Consortium).
- A Phase II Trial of Bevacizumab and Erlotinib in Patients with Advanced Biliary Tumors (NCI study in collaboration with Mayo Phase II Consortium).